Related Experiment Video
Updated: Jul 13, 2026

Studying Chronic Exposure of Mice to Ultraviolet B Radiation
Published on: August 19, 2025
Narrowband UVB therapy for vitiligo: does the repigmentation last?
J C Sitek1, M Loeb, J R Ronnevig
1Department of Dermatology, Ulleval University Hospital, Oslo, Norway. jcsitek@online.no
Background:
Since 1997, a number of trials have shown promising results in treating generalized vitiligo with narrowband ultraviolet B (UVB) both in adults and children. However, there is little knowledge concerning the duration and permanency of the treatment-induced repigmentation.
Objective:
Our main objective was to perform a follow-up trial of successfully treated patients receiving narrowband UVB for generalized vitiligo.
Methods:
We have investigated to what degree the treatment-induced repigmentation remains stable for up to 2 years post-treatment. We performed an initial open trial including 31 patients with generalized vitiligo. They received narrowband UVB thrice weekly for up to 12 months. Patients experiencing > 75% repigmentation were defined responders and were included in the follow-up trial. Responders were followed every 6 months for up to 2 years after cessation of treatment. We observed the pigmentation status and registered any changes indicating loss of pigmentation and relapse.
Results:
Eleven of the 31 treated patients were included in the follow-up trial. Six patients had relapse and five patients had stable response 24 months after cessation of treatment. Four out of six relapses were within 6 months post-treatment.
Conclusion:
In our study population of 31 patients with generalized vitiligo, five patients (16%) experienced > 75% stable repigmentation 2 years after cessation of a treatment programme of up to 1 years narrowband UVB therapy.
Related Concept Videos
Acne Infection
Photoreceptors and Visual Pathways
